PHM Pharma Mar, S.A.
70.00EUR-1.48%Mkt Cap: 1.32B $P/E: 23.26Today
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, res…
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.45BUSDP/E 35.2
$44.29BUSD
$42.34BUSDP/E 18.1
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.69BUSDP/E 27.4
$20.52BUSDP/E 27.1
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Pharma Mar SA (PHMMF) Q2 2026 Earnings Call Highlights: Strong Royalty Growth and European ... Pharma Mar SA (PHMMF) reports a 46% surge in royalty income and European approval for Zepzelca, but faces a sharp EBITDA drop due to non-recurring revenues. | ||